ClinicalTrials.gg
CompletedNCT03339583Updated Sep 16, 2019Results posted

Effectiveness of BBT-I and Zopiclone for Chronic Insomnia

A Phase 2 interventional study of Brief behavioral therapy and Zopiclone in Insomnia Chronic, sponsored by I.M. Sechenov First Moscow State Medical University. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-09-16.

Sponsored by I.M. Sechenov First Moscow State Medical University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Apr 2015, registered Oct 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Background: Importance of chronic insomnia (CI) problem is determined by its high prevalence rate, comorbidity and resistance to the treatment. Although cognitive behavior treatment of insomnia (CBT-I) remains the recommended treatment for CI it has disadvantages of time consuming and low treatment response. Hence shortened and simplified behavioral approaches such as Brief Behavioral therapy of insomnia (BBT-I) are developed. The aim of the present study is to test the effectiveness of BBT-I program for chronic insomnia in comparison with zopiclone in Russian population. The anthropometric, psychological and polysomnographic characteristics of patients were measured to find predictors of effectiveness of each method.

Participants: 42 adults (14 males, 28 females, mean age 54 years) meeting the criteria for CI according International classification of sleep disorders-3 Methods: Participants were randomized into two groups. Each group passed 2-week courses of treatment by brief behavior treatment of insomnia (BBT-I) and zopiclone in different orders with 2-week washout period between the courses. Participants underwent in-lab polysomnography prior to the treatment and completed questionnaires (Insomnia Severity Index (ISI), Dysfunctional beliefs about sleep scale (DBAS), Beck Depression Inventory (BDI) and others) in the beginning and the end of each course

Read the detailed description

The study had a crossover design implying that every patient underwent two different treatment courses in random sequence: hypnotic or structured educational program (BBT-I) delivered in two sessions.

Each treatment course was separated by 2-weeks washout period that provided the opportunity to evaluate the sustainability of treatment effect.

Before and after each treatment course and after each washout period subjects completed set of questionnaires.

The total duration of the study was 8 weeks in which 6 visits including 1 night polysomnography (PSG), 2 face-to-face structured educational program sessions and 5 diagnostic interviews have been performed.

Participants A sample of 42 adults (14 males, 28 females, mean age 54 years from 29 to 80 years) meeting the criteria for chronic insomnia according ICSD-3 was recruited from outpatient care of Department of sleep medicine of University Hospital №3 of I.M. Sechenov First Moscow State Medical University. All participants were informed about the nature, purpose, risks, and discomforts that could arise from their participation, and about their right to withdraw at any time. Subjects documented their willingness to participate by signing the informed consent form, approved by local Ethic Committee.

Treatment methods. BBT-I program includes two weekly one hour individual sessions; Hypnotic (zopiclone) in a dose of 7,5 mg has to be taken 30 minutes before bedtime for two weeks

Measures Questionnaires. During the first visit patients underwent structured clinical interview and filled in self-report questionnaires: Beck Depression Inventory (BDI), State-trait anxiety inventory (STAI), Toronto Alexithymia Scale - short version (TAS-20) , Big Five Questionnaire (BFQ-2R), Pittsburgh Sleep Quality Index (PSQI), Insomnia Severity Index (ISI), Dysfunctional beliefs about sleep scale (DBAS), Sleep hygiene index (SHI).

During the next 4 visits participants repeatedly underwent diagnostic tests included BDI, STAI, PSQI, ISI, DBAS, SHI.

Participants kept daily sleep diaries where they recorded bedtime and morning rise time, sleep onset latency (SOL), number of night awakenings and time of wakefulness after sleep onset before waking up (WASO) for the whole study period.

On the last visit participants completed questionnaire for assessment of effectiveness of treatment along with diagnostic routine. Patients were asked to rank the effectiveness of proposed methods of treatment (didactic presentation, stimulus control, sleep restriction, relaxing recording and zopiclone) in ascending order from 1 to 5 points (5 seems most effective).

Polysomnography. Participants underwent in-lab PSG (1 night without adaptation night) prior to the treatment in order to exclude other disorders producing subjective sleep complaints (sleep apnea, periodic limb movements disorder). Standard polysomnography montage including 6 monopolar electroencephalography (EEG) channels; 1 submental electromyogram (EMG) channel; 2 electrooculogram (EOG) channels; 2 EMG channels of the right and left tibialis anterior muscles; 1 electrocardiogram channel; oronasal airflow pressure; thoracic and abdominal efforts; respiratory sound; oxygen saturation; body position with videomonitoring was performed. The objective sleep measures included total sleep time (TST), sleep-onset latency, wake time after sleep onset (WASO), number of awakenings, sleep efficiency (the ratio of TST to time spent in bed multiplied on 100%, SE), percentage of sleep stages. PSG data were analysed according the 2007 American Academy of Sleep Medicine criteria including its revision in 2012.

02

Conditions studied

  • Insomnia Chronic

Keywords

  • chronic insomnia
  • brief behavioral treatment
  • behavioral treatment
  • insomnia severity index
  • predictors
  • treatment response
03

In context

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

This study's enrollment of 42 is below the median of 68 across 2,359 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

I.M. Sechenov First Moscow State Medical University is the lead sponsor of 137 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

meeting the criteria for chronic insomnia according ICSD-3 willingness to take part in the study and signed form

Exclusion criteria

Exclusion Criteria:

  1. unability to stop taking medications that have a proven impact on sleep at least one week before and during the study;
  2. history of alcohol or drug abuse;
  3. major depressive disorder or other severe mental disorder identified by a clinical assessment and medical history;
  4. dementia;
  5. pregnancy or lactation;
  6. shift or night work;
  7. medical problems that would be a direct cause of sleep complaints: moderate/severe sleep apnea, defined as an apnea-hypopnea index of ≥15 events per hour, periodic limb movement disorder defined as a periodic leg movement index ≥15 events per hour or restless legs syndrome;
  8. other serious chronic conditions or exacerbation of chronic disorder preventing further participation.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    zopiclone first group

    underwent the medication therapy (zopiclone) for the first two weeks followed by brief behavioral therapy

    Behavioral: Brief behavioral therapy · Drug: Zopiclone

  • Experimental
    BBT-I first group

    received two-week brief behavioral therapy followed by medication therapy (zopiclone).

    Behavioral: Brief behavioral therapy · Drug: Zopiclone

Interventions

  • BehavioralBrief behavioral therapy

    program included a question-and-answer part; a didactic presentation of sleep regulation mechanisms; the review of causes of onset and chronification of illness; an examination of patient's sleep log; explanation of sleep restriction method and prescription of individual regimen of sleep; explanation of stimulus control method; sleep hygiene education; discussion of relaxation techniques. Participants were supplied with 32 minute audio recording "Relaxation and refreshment session for insomnia" created for this study by Dr. A.Tabidze with verbal relaxing instructions with quiet musical composition behind it. Participants were instructed to listen to this recording in headphones each day for 2-week BBT-I period after laying into bed and turning the light off.

    Also known as: BBT-I

  • zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks

    Also known as: hypnotic

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index

    self reported insomnia symptoms severity by Insomnia severity index . Each item is scored 0 (no problem) - 4 (very big problem) with total between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

    Time frame: For BBT-I-first group: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/Month 1); For zopiclone-first group: after washout period (Day 28/Week 4/Month 1) after second treatment course (Day 42/Week 6/Month 2)

Secondary outcomes

  1. Beck Depression Inventory

    21-item questionnaire assessing (on 4-point Likert scales) the intensity of depressive symptoms in the past week. Minimum score 0, maximum score 63 points. Higher total score represents more severe depressive symptoms

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

  2. State Anxiety Subscale (STAI)

    State trait anxiety scale is a 2-part questionnaire assessing state (situational) and trait anxiety. State anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

  3. Dysfunctional Beliefs About Sleep Scale

    questionnaire assessing sleep related cognitions in 16 item rated on a 10-point Likert scale. Minimum score is 0, maximum score is 160 points. Higher total score represents more intensive disfunctional beliefs

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

  4. Sleep Hygiene Index

    questionnaire assessing sleep related behavior in 13 item rated on a 5-point Likert scale.Minimum score 13 points and maximum score 65 points. Higher total score represents worse sleep hygiene

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

  5. Pittsburgh Sleep Quality Index

    19-item questionnaire evaluating sleep quality over the past month. The first 4 items are open questions, items 5 to 19 are rated on a 4-point Likert scale. A total score range from 0 to 21. A score \> 5 suggests poor sleep quality.

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

  6. Trait Anxiety Subscale (STAI)

    STAI is a 2-part questionnaire assessing state (situational) and trait anxiety. Trait anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for each subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms

    Time frame: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)

Other outcomes

  1. Toronto Alexithymia Scale (TAS-20)

    Degree of alexithymia evaluated by Toronto Alexithymia scale (20 questions) Measure Description: 0-100 scores. higher values represent worse outcome

    Time frame: once at baseline assessment

  2. Sleep Latency

    time period from bedding to sleep onset

    Time frame: once at baseline assessment

  3. Total Sleep Time

    total sleep episode minus wake time

    Time frame: once at baseline assessment

  4. Sleep Efficiency

    Prercentage of Total Bed Time

    Time frame: once at baseline assessment

  5. Wake After Sleep Onset

    total duration of all periods of wakefulness between sleep onset and final awakening in the morning

    Time frame: once at baseline assessment

  6. Amount of Awakenings

    Number of awakenings between sleep onset and final morning awakening

    Time frame: once at baseline assessment

  7. N1 NREM Sleep Percentage

    Percentage of Total Sleep Time

    Time frame: once at baseline assessment

  8. N2 NREM Sleep Percentage

    Percentage of Total Sleep Time

    Time frame: once at baseline assessment

  9. N3 NREM Sleep Percentage

    Percentage of Total Sleep Time

    Time frame: once at baseline assessment

  10. REM Sleep Percentage

    Percentage of Total Sleep Time

    Time frame: once at baseline assessment

07

Results

Posted Jun 17, 2019

Participant flow

First Intervention (14 Days)
Participant flow — First Intervention (14 Days)
MilestoneZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Started1923
Completed1823
Not completed10
Withdrew: Adverse event10
Washout (14 Days)
Participant flow — Washout (14 Days)
MilestoneZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Started1823
Completed1823
Not completed00
Second Intervention (14 Days)
Participant flow — Second Intervention (14 Days)
MilestoneZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Started1823
Completed1821
Not completed02
Withdrew: Unrelated acute exacerbation01
Withdrew: Adverse event01
Follow-up (14 Days)
Participant flow — Follow-up (14 Days)
MilestoneZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Started1821
Completed1218
Not completed63
Withdrew: Physician decision63

Outcome measures

PrimaryInsomnia Severity Index

self reported insomnia symptoms severity by Insomnia severity index . Each item is scored 0 (no problem) - 4 (very big problem) with total between 0-28 (absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).

Time frame:
For BBT-I-first group: on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/Month 1); For zopiclone-first group: after washout period (Day 28/Week 4/Month 1) after second treatment course (Day 42/Week 6/Month 2)
Reported as:
Mean · units on a scale
Insomnia Severity Index
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination18.6 ± 5.218.9 ± 3.9
First treatment course13.1 ± 5.214.0 ± 5.7
After washout14.3 ± 6.316.1 ± 4.7
Second treatment course12.1 ± 6.112.8 ± 5.4
After follow-up13.1 ± 4.712.7 ± 5.9
SecondaryBeck Depression Inventory

21-item questionnaire assessing (on 4-point Likert scales) the intensity of depressive symptoms in the past week. Minimum score 0, maximum score 63 points. Higher total score represents more severe depressive symptoms

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
Beck Depression Inventory
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination11.5 ± 6.89.3 ± 7.3
first treatment course8.4 ± 6.89.4 ± 8.2
After washout8.4 ± 8.29.8 ± 5.1
Second treatment course9.2 ± 9.08.5 ± 6.2
After follow-up9.0 ± 8.17.4 ± 6.2
SecondaryState Anxiety Subscale (STAI)

State trait anxiety scale is a 2-part questionnaire assessing state (situational) and trait anxiety. State anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
State Anxiety Subscale (STAI)
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination45.1 ± 8.843.2 ± 8.5
First treatment course43.8 ± 8.644.3 ± 9.1
After washout45.5 ± 9.044.5 ± 9.8
Second treatment course45.1 ± 9.144.0 ± 9.6
After follow-up46.9 ± 6.544.2 ± 10.4
SecondaryDysfunctional Beliefs About Sleep Scale

questionnaire assessing sleep related cognitions in 16 item rated on a 10-point Likert scale. Minimum score is 0, maximum score is 160 points. Higher total score represents more intensive disfunctional beliefs

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
Dysfunctional Beliefs About Sleep Scale
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination105.2 ± 29.093.2 ± 35.0
First treatment course83.8 ± 34.896.4 ± 36.4
After washout84.76 ± 36.9103.6 ± 32.2
Second treatment course84.5 ± 39.889.2 ± 35.4
After follow-up62.8 ± 34.592.0 ± 34.5
SecondarySleep Hygiene Index

questionnaire assessing sleep related behavior in 13 item rated on a 5-point Likert scale.Minimum score 13 points and maximum score 65 points. Higher total score represents worse sleep hygiene

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
Sleep Hygiene Index
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination26.8 ± 7.425.2 ± 5.9
First treatment course24.0 ± 5.625.0 ± 6.9
After washout24.7 ± 6.025.5 ± 7.4
Second treatment course24.7 ± 6.624.3 ± 6.6
After follow-up23.8 ± 6.525.2 ± 7.6
SecondaryPittsburgh Sleep Quality Index

19-item questionnaire evaluating sleep quality over the past month. The first 4 items are open questions, items 5 to 19 are rated on a 4-point Likert scale. A total score range from 0 to 21. A score \> 5 suggests poor sleep quality.

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
Pittsburgh Sleep Quality Index
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination13.4 ± 3.611.9 ± 4.1
First treatment course10.5 ± 4.511.3 ± 4.1
After washout11.3 ± 4.412.7 ± 3.8
Second treatment course10.8 ± 4.411.7 ± 4.8
After follow-up11.2 ± 4.911.1 ± 4.7
SecondaryTrait Anxiety Subscale (STAI)

STAI is a 2-part questionnaire assessing state (situational) and trait anxiety. Trait anxiety subscale comprise 20 items rated on a 4-point Likert scale. Minimum score for each subscale is 20 and maximum score is 80 points. Higher total score indicates more severe anxiety symptoms

Time frame:
on the initial examination (Day 1/Week 1/Month 1), after first treatment course (Day 14/Week 2/ Month 1), after washout period (Day 28/ Week 4/Month 1), after second treatment course (Day 42/Week 6/Month 8), after second washout (Day 56/Week 8/ Month 2)
Reported as:
Mean · units on a scale
Trait Anxiety Subscale (STAI)
units on a scaleBBT-I First GroupZopiclone First Group
Baseline/initial examination48.7 ± 6.948.3 ± 8.1
First treatment course48.3 ± 8.148.3 ± 8.6
After washout48.6 ± 7.649.3 ± 7.0
Second treatment course46.3 ± 9.548.5 ± 8.3
After follow-up46.3 ± 8.648.8 ± 10.7
Other pre-specifiedToronto Alexithymia Scale (TAS-20)

Degree of alexithymia evaluated by Toronto Alexithymia scale (20 questions) Measure Description: 0-100 scores. higher values represent worse outcome

Time frame:
once at baseline assessment
Reported as:
Mean · scores on a scale
Toronto Alexithymia Scale (TAS-20)
scores on a scaleZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Toronto Alexithymia Scale (TAS-20)49.83 ± 15.949.33 ± 10.0
Other pre-specifiedSleep Latency

time period from bedding to sleep onset

Time frame:
once at baseline assessment
Reported as:
Mean · minutes
Sleep Latency
minutesZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Sleep Latency38.53 ± 21.754.5 ± 51.0
Other pre-specifiedTotal Sleep Time

total sleep episode minus wake time

Time frame:
once at baseline assessment
Reported as:
Mean · hours
Total Sleep Time
hoursZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Total Sleep Time5.72 ± 1.65.51 ± 1.6
Other pre-specifiedSleep Efficiency

Prercentage of Total Bed Time

Time frame:
once at baseline assessment
Reported as:
Mean · percentage of polysomnogram time
Sleep Efficiency
percentage of polysomnogram timeZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Sleep Efficiency64.68 ± 17.963.29 ± 18.0
Other pre-specifiedWake After Sleep Onset

total duration of all periods of wakefulness between sleep onset and final awakening in the morning

Time frame:
once at baseline assessment
Reported as:
Mean · minutes
Wake After Sleep Onset
minutesZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Wake After Sleep Onset102.39 ± 69.0104.75 ± 76.1
Other pre-specifiedAmount of Awakenings

Number of awakenings between sleep onset and final morning awakening

Time frame:
once at baseline assessment
Reported as:
Mean · awakenings
Amount of Awakenings
awakeningsZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
Amount of Awakenings13.78 ± 6.113.25 ± 6.9
Other pre-specifiedN1 NREM Sleep Percentage

Percentage of Total Sleep Time

Time frame:
once at baseline assessment
Reported as:
Mean · percentage of total sleep time
N1 NREM Sleep Percentage
percentage of total sleep timeZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
N1 NREM Sleep Percentage4.16 ± 3.13.70 ± 3.3
Other pre-specifiedN2 NREM Sleep Percentage

Percentage of Total Sleep Time

Time frame:
once at baseline assessment
Reported as:
Mean · percentage of time
N2 NREM Sleep Percentage
percentage of timeZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
N2 NREM Sleep Percentage64.19 ± 10.262.58 ± 8.4
Other pre-specifiedN3 NREM Sleep Percentage

Percentage of Total Sleep Time

Time frame:
once at baseline assessment
Reported as:
Mean · percentage of total sleep time
N3 NREM Sleep Percentage
percentage of total sleep timeZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
N3 NREM Sleep Percentage17.52 ± 8.816.39 ± 7.0
Other pre-specifiedREM Sleep Percentage

Percentage of Total Sleep Time

Time frame:
once at baseline assessment
Reported as:
Mean · percentage of total sleep time
REM Sleep Percentage
percentage of total sleep timeZopiclone First, Then BBT-IBBT-I First, Then Zopiclone
REM Sleep Percentage14.1 ± 5.517.0 ± 7.7

Adverse events

Collected over 2 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BBT-I0/42 (0%)0/42 (0%)0/42 (0%)
Zopiclone0/41 (0%)0/41 (0%)2/41 (4.9%)
Most frequent other events
Most frequent other events
EventBBT-IZopiclone
rash hypersensitivity reaction to zopicloneSkin and subcutaneous tissue disorders0/421/41
bitter tasteHepatobiliary disorders0/421/41

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Zopiclone First GroupBBT-I First GroupTotal
<=18 years000
Between 18 and 65 years132033
>=65 years639
Age, Continuous
Age, Continuous(years)Zopiclone First GroupBBT-I First GroupTotal
Mean55.0 ± 14.847.5 ± 14.150.7 ± 14.5
Sex: Female, Male
Sex: Female, Male(Participants)Zopiclone First GroupBBT-I First GroupTotal
Female111627
Male8715
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Zopiclone First GroupBBT-I First GroupTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Zopiclone First GroupBBT-I First GroupTotal
Russia192342
Beck depression inventory
Beck depression inventory(units on a scale)Zopiclone First GroupBBT-I First GroupTotal
Mean10.8 ± 5.012.8 ± 7.212.1 ± 6.1
State anxiety inventory
State anxiety inventory(units on a scale)Zopiclone First GroupBBT-I First GroupTotal
Mean43.5 ± 8.746.9 ± 6.945.3 ± 8.1
trait anxiety inventory
trait anxiety inventory(units on a scale)Zopiclone First GroupBBT-I First GroupTotal
Mean49.6 ± 8.349.1 ± 7.249.3 ± 7.5

14 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Pchelina PV, Tabidze AA, Poluektov MG. [Comparative study of effectiveness of cognitive-behavior therapy and zopiclone for chronic insomnia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(4. Vyp. 2):48-55. doi: 10.17116/jnevro20171174248-55. Russian. PubMed 28777364 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Since our lab has no plans to continue or extend the registered study we are not planning share individual patient data with other researches

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Mar 2017, 23 months.

Results were first posted in Jun 2019, 2 years 3 months after primary completion.

Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Nov 13, 2017
StartActual
Apr 7, 2015
Primary completionActual
Mar 14, 2017
CompletionActual
Mar 14, 2017
Results first posted
Jun 17, 2019
Last update
Sep 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03339583
Responsible party
Polina Pchelina (Postgraduate student. Institute of Professional Education, Chair of Neurology. I.M. Sechenov First Moscow State Medical University, I.M. Sechenov First Moscow State Medical University) — Principal investigator
First posted
Nov 13, 2017
Start date
Apr 7, 2015
Primary completion
Mar 14, 2017
Completion
Mar 14, 2017
Results posted
Jun 17, 2019
Last update
Sep 16, 2019

Study contacts

Polina Pchelina, PG student
principal investigator · I.M. Sechenov First Moscow State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zopiclone

Start the discussion